New Delhi | Agencies: A Mumbai-based company 'Glenmark Pharmaceuticals' has began phase three of clinical trials on antiviral tablet Favipiravir to check its efficacy on COVID-19 patients in India, reported news agency ANI.

The company had obtained approval from Drug Controller General of India last month to conduct clinical trials.

In a statement, Glenmark said that it is the first country to initiate phase III clinical trials on Facipiravir for COVID-19 patients in India.

Clinical trials have commenced and over ten leading government and private hospitals are being enrolled for the study, it added.

Glenmark estimates the completion of studies by July/ August, it said.

As per approved clinical trial protocol, 150 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio of Favipiravir witj standard supportive care.

The maximum treatment duration is 14 days and the total study duration would be maximum of 28 days from randomisation.

Speaking to ANI, Monika Tandon, Vice President and Head of Clinical Development, Global Specialty/Branded Portfolio at Glenmark Pharmaceuticals, said, "Several health and medical experts both in and outside of Glenmark are eager to see the effect that Favipiravir has on Covid-19 cases."

"We believe the study results will be significant as there is currently no effective treatment for the virus. The data we get from these trials will point us in a clearer direction with regard to COVID-19 treatment and management," she added.

The company said that it aims to launch the cure for coronavirus patients as soon as possible.

Favipiravir is a generic version of Japan-based Fujifilm Toyama Chemical's Avigan. It has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with operations in over 50 countries. Its key therapy focus areas globally are oncology, respiratory and dermatology.

(with PTI, ANI inputs)

Posted By: James Kuanal